GlassScriptPhysician profile
Coty D Wade
NPI 1144305053
$6,748.54
in general payments reported to CMS, 2019-2025
47 companies · $36.74 in 2025
The $36.74 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,148 · 2022: $1,945 · 2023: $1,969 · 2024: $650 · 2025: $36.74.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,656.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,655.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $815.13 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $569.37 | 2021-2024 | Repatha, Otezla, Prolia |
| Abbvie INC. | $533.04 | 2021-2023 | |
| Glaxosmithkline, LLC. | $507.74 | 2021-2023 | Trelegy Ellipta |
| Optinose US, INC. | $452.45 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $393.11 | 2021-2024 | Farxiga, Airsupra |
| Takeda Pharmaceuticals U.S.A., INC. | $359.52 | 2021-2024 | Trintellix |
| Lilly USA, LLC | $308.24 | 2022-2024 | Mounjaro, Jardiance, Emgality |
| Abbott Laboratories | $298.26 | 2021-2023 | Freestyle Libre 2 |
| Bayer Healthcare Pharmaceuticals INC. | $247.95 | 2022-2023 | |
| Pfizer INC. | $215.20 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $192.47 | 2021-2024 | Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $191.35 | 2022 | |
| Esperion Therapeutics, INC. | $178.33 | 2021-2024 | Nexletol |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $131.40 | 2021-2023 | Xifaxan |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Coty Wade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.